Shareholders With Considerable Losses Have Chance to Direct the Ocugen, Inc. Class Action Lawsuit

San Diego, California–(Newsfile Corp. – July 15, 2021) – The Ocugen, Inc. class motion lawsuit rates Ocugen, Inc. (NASDAQ: OCGN) and specific of its best executives with violations of the Securities Trade Act of 1934 and seeks to signify purchasers of Ocugen securities amongst February 2, 2021 and June 10, 2021, inclusive (the “Class Period of time”). The Ocugen course action lawsuit (Nicanor v. Ocugen, Inc., No. 21-cv-02725) was commenced on June 17, 2021 in the Eastern District of Pennsylvania and is assigned to Judge C. Darnell Jones, II.

If you experienced considerable losses and desire to provide as direct plaintiff of the Ocugen course action lawsuit, make sure you supply your data by clicking listed here. You can also make contact with legal professional J.C. Sanchez of Robbins Geller by contacting 800/449-4900 or by way of e-mail at [email protected]. Direct plaintiff motions for the Ocugen class motion lawsuit need to be submitted with the court docket no later than August 17, 2021.

Circumstance ALLEGATIONS: The Ocugen course motion lawsuit alleges that, during the Course Time period, defendants created untrue and misleading statements and failed to disclose that: (i) the data that Ocugen submitted to the U.S. Foods and Drug Administration (“Fda”) was insufficient to help an Emergency Use Authorization (“EUA”) (ii) Ocugen would not file an EUA with the Food and drug administration and (iii) as a result, Ocugen’s financial statements, as properly as defendants’ statements about Ocugen’s company, operations, and prospective clients were being bogus and misleading and/or lacked a sensible basis.

On June 10, 2021, Ocugen issued a press release asserting that it would pursue a biologics license application (“BLA”) with the Food and drug administration as a substitute of the earlier announced EUA. In executing so, Ocugen disclosed that “[t]he Fda provided feedback to Ocugen concerning the Learn File the Corporation had earlier submitted and suggested that Ocugen pursue a BLA submission alternatively of an EUA software for its vaccine candidate and requested extra data and facts. Ocugen is in discussions with the Fda to have an understanding of the added info expected to help a BLA submission. The Business anticipates that details from an more clinical trial will be expected to assist the submission.” On this information, the price tag of Ocugen’s inventory fell far more than 28%, detrimental buyers.

THE Lead PLAINTIFF Method: The Private Securities Litigation Reform Act of 1995 permits any trader who procured Ocugen securities through the Class Period of time to seek appointment as guide plaintiff in the Ocugen class motion lawsuit. A guide plaintiff is typically the movant with the biggest economic curiosity in the aid sought by the putative class who is also regular and adequate of the putative class. A direct plaintiff functions on behalf of all other class customers in directing the Ocugen course action lawsuit. The guide plaintiff can pick a legislation agency of its alternative to litigate the Ocugen course action lawsuit. An investor’s ability to share in any opportunity future restoration of the Ocugen course action lawsuit is not dependent upon serving as direct plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 places of work nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. regulation agency representing buyers in securities course steps. Robbins Geller lawyers have obtained lots of of the largest shareholder recoveries in background, such as the largest securities course motion recovery at any time – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Motion Services Top 50 Report rated Robbins Geller 1st for recovering $1.6 billion for investors previous year, much more than double the total recovered by any other securities plaintiffs’ business. Please visit for much more facts.

Attorney advertising.

Previous results do not promise upcoming outcomes.

Providers may well be performed by lawyers in any of our places of work.

Get in touch with:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]

To view the source model of this push launch, make sure you stop by